JP2018522875A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522875A5 JP2018522875A5 JP2017568131A JP2017568131A JP2018522875A5 JP 2018522875 A5 JP2018522875 A5 JP 2018522875A5 JP 2017568131 A JP2017568131 A JP 2017568131A JP 2017568131 A JP2017568131 A JP 2017568131A JP 2018522875 A5 JP2018522875 A5 JP 2018522875A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- weight
- treatment
- compound
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 235000019271 petrolatum Nutrition 0.000 claims 3
- 230000001823 pruritic effect Effects 0.000 claims 3
- 208000017520 skin disease Diseases 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 239000002480 mineral oil Substances 0.000 claims 2
- 235000010446 mineral oil Nutrition 0.000 claims 2
- 230000008591 skin barrier function Effects 0.000 claims 2
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 2
- 239000003871 white petrolatum Substances 0.000 claims 2
- TYNLGDBUJLVSMA-UHFFFAOYSA-N 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000032544 Cicatrix Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims 1
- 208000011219 Netherton syndrome Diseases 0.000 claims 1
- 208000012868 Overgrowth Diseases 0.000 claims 1
- 239000004264 Petrolatum Substances 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000037365 barrier function of the epidermis Effects 0.000 claims 1
- 229960000541 cetyl alcohol Drugs 0.000 claims 1
- 229960004590 diacerein Drugs 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 230000002390 hyperplastic effect Effects 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940066842 petrolatum Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 230000037387 scars Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022125318A JP7578651B2 (ja) | 2015-07-01 | 2022-08-05 | ジアセレインまたはレインの局所製剤およびその使用 |
| JP2024122108A JP2024164022A (ja) | 2015-07-01 | 2024-07-29 | ジアセレインまたはレインの局所製剤およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562187743P | 2015-07-01 | 2015-07-01 | |
| US62/187,743 | 2015-07-01 | ||
| PCT/US2016/040287 WO2017004319A1 (en) | 2015-07-01 | 2016-06-30 | Diacerein or rhein topical formulations and uses thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022125318A Division JP7578651B2 (ja) | 2015-07-01 | 2022-08-05 | ジアセレインまたはレインの局所製剤およびその使用 |
| JP2024122108A Division JP2024164022A (ja) | 2015-07-01 | 2024-07-29 | ジアセレインまたはレインの局所製剤およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522875A JP2018522875A (ja) | 2018-08-16 |
| JP2018522875A5 true JP2018522875A5 (enExample) | 2021-01-14 |
| JP7577428B2 JP7577428B2 (ja) | 2024-11-05 |
Family
ID=57609470
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568131A Active JP7577428B2 (ja) | 2015-07-01 | 2016-06-30 | ジアセレインまたはレインの局所製剤およびその使用 |
| JP2022125318A Active JP7578651B2 (ja) | 2015-07-01 | 2022-08-05 | ジアセレインまたはレインの局所製剤およびその使用 |
| JP2024122108A Pending JP2024164022A (ja) | 2015-07-01 | 2024-07-29 | ジアセレインまたはレインの局所製剤およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022125318A Active JP7578651B2 (ja) | 2015-07-01 | 2022-08-05 | ジアセレインまたはレインの局所製剤およびその使用 |
| JP2024122108A Pending JP2024164022A (ja) | 2015-07-01 | 2024-07-29 | ジアセレインまたはレインの局所製剤およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9744131B2 (enExample) |
| EP (1) | EP3316879A4 (enExample) |
| JP (3) | JP7577428B2 (enExample) |
| KR (1) | KR102702557B1 (enExample) |
| CN (2) | CN107921013A (enExample) |
| AU (2) | AU2016287636B2 (enExample) |
| CA (1) | CA2990948C (enExample) |
| HK (1) | HK1249057A1 (enExample) |
| IL (1) | IL256585B (enExample) |
| MX (1) | MX373702B (enExample) |
| TW (1) | TWI723032B (enExample) |
| WO (1) | WO2017004319A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180037261A (ko) * | 2015-08-17 | 2018-04-11 | 티더블유아이 바이오테크놀로지 인코포레이티드 | Asc의 발현, nlrp3의 발현, 및/또는 nlrp3 인플라마솜 복합체의 형성 저해용 디아세레인 또는 이의 유사체 |
| EP3570835B1 (en) * | 2017-01-19 | 2023-08-09 | TWI Biotechnology, Inc. | Diacerein for preventing or treating immunoinflammatory dermal disorders |
| CN106692037B (zh) * | 2017-01-24 | 2020-02-18 | 中南大学湘雅医院 | 大黄酸超分子水凝胶及其制备方法和应用 |
| CN107823126B (zh) * | 2017-12-04 | 2020-03-24 | 广东药科大学 | 双醋瑞因注射型温敏凝胶及其制备方法 |
| CN111265508B (zh) * | 2018-12-05 | 2022-03-25 | 中检科医药科技(北京)集团有限公司 | 双醋瑞因在制备抗病毒药物及治疗病毒感染中的用途 |
| CN109758421A (zh) * | 2019-03-27 | 2019-05-17 | 毕波 | 一种蓝氧抗菌灭毒软膏及其制备方法 |
| US20220265577A1 (en) * | 2019-08-03 | 2022-08-25 | Venkateswarlu Vobalaboina | Process for the preparation of anthraquinone topical formulation |
| CN110585120B (zh) * | 2019-10-08 | 2020-11-27 | 中南大学 | 一种可注射双醋瑞因水凝胶及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4018764B2 (ja) * | 1996-10-18 | 2007-12-05 | 正規 小菅 | 津液改善用皮膚外用剤 |
| FR2757397B1 (fr) | 1996-12-23 | 1999-03-05 | Mazal Pharma | Composition pharmaceutique a base de rheine ou de diacerheine a biodisponibilite amelioree |
| US7704522B2 (en) * | 2004-09-08 | 2010-04-27 | Clyde Morgan | Topical medicament |
| US20100285114A1 (en) * | 2007-09-27 | 2010-11-11 | Rahul Dabre | Pharmaceutical compositions of rhein or diacerein |
| US20090093509A1 (en) * | 2007-10-08 | 2009-04-09 | Tahir Nazir | Methods and Compositions for the Treatment of Pruritus |
| WO2009133430A1 (en) * | 2008-04-30 | 2009-11-05 | Wockhardt Research Centre | Topical compositions of rhein or diacerein |
| TWI473610B (zh) * | 2008-10-28 | 2015-02-21 | Twi Biotechnology Inc | 包含雙醋瑞因（ｄｉａｃｅｒｅｉｎ）之醫藥組合物 |
| FR2949044B1 (fr) * | 2009-08-12 | 2021-05-07 | Expanscience Lab | Composition comprenant une fraction d'insaponifiable |
| MX2012011517A (es) | 2010-04-08 | 2012-11-29 | Twi Biotechnology Inc | El uso de diacereina como una terapia adyuvante para diabetes. |
| WO2012013670A1 (en) * | 2010-07-29 | 2012-02-02 | University Of Geneva | Process for the esterification of hyaluronic acid with hydrophobic organic compounds |
| JP6012639B2 (ja) | 2011-03-11 | 2016-10-25 | ティダブリューアイ・バイオテクノロジー・インコーポレイテッドＴＷＩ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． | 高尿酸血症および高尿酸血症関連代謝障害を治療するための方法および組成物 |
-
2016
- 2016-06-30 US US15/198,728 patent/US9744131B2/en active Active
- 2016-06-30 JP JP2017568131A patent/JP7577428B2/ja active Active
- 2016-06-30 AU AU2016287636A patent/AU2016287636B2/en active Active
- 2016-06-30 CN CN201680050004.8A patent/CN107921013A/zh active Pending
- 2016-06-30 HK HK18108955.6A patent/HK1249057A1/zh unknown
- 2016-06-30 EP EP16818753.2A patent/EP3316879A4/en active Pending
- 2016-06-30 CN CN202311670907.4A patent/CN117482078A/zh active Pending
- 2016-06-30 KR KR1020187002677A patent/KR102702557B1/ko active Active
- 2016-06-30 CA CA2990948A patent/CA2990948C/en active Active
- 2016-06-30 MX MX2018000264A patent/MX373702B/es active IP Right Grant
- 2016-06-30 WO PCT/US2016/040287 patent/WO2017004319A1/en not_active Ceased
- 2016-07-01 TW TW105120973A patent/TWI723032B/zh active
-
2017
- 2017-12-26 IL IL256585A patent/IL256585B/en active IP Right Grant
-
2021
- 2021-09-08 AU AU2021229177A patent/AU2021229177B2/en active Active
-
2022
- 2022-08-05 JP JP2022125318A patent/JP7578651B2/ja active Active
-
2024
- 2024-07-29 JP JP2024122108A patent/JP2024164022A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522875A5 (enExample) | ||
| JP2024164022A5 (enExample) | ||
| JP2014505733A5 (enExample) | ||
| JP6589086B2 (ja) | 抗菌薬の組成物および製剤、その製造法および微生物感染症の治療方法 | |
| JP2016516808A5 (enExample) | ||
| MX377629B (es) | Composiciones farmacéuticas tópicas. | |
| CA2907721A1 (en) | Compositions and methods for topical delivery of prostaglandins to subcutaneous fat | |
| PE20130216A1 (es) | Formulacion topica para un inhibidor de jak | |
| BR112012010083B8 (pt) | Composição farmacêutica tópica de liberação sustentada e uso relacionado | |
| MX382192B (es) | Composiciones de canabinoide y usos. | |
| JP2013542930A5 (enExample) | ||
| EP2768495A1 (en) | Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of use thereof | |
| AR085662A1 (es) | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia | |
| JP2016513650A5 (enExample) | ||
| BR112015023409A8 (pt) | complexo iônico, composição farmacêutica compreendendo o referido complexo, seu uso e métodos de produção do referido complexo | |
| HRP20180956T1 (hr) | Nanočestice, postupak dobivanja i njihova primjena kao nosača amfipatičnih ili hidrofobnih molekula u medicini, uključujući i terapiju karcinoma, kao i prehrambenih spojeva | |
| AU2013306281B2 (en) | Retinoids and use thereof | |
| JP7229285B2 (ja) | １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法 | |
| JP2014516962A5 (enExample) | ||
| EP2723330A1 (de) | Vasokonstriktorhaltiges kombinationstherapeutikum | |
| BR112015027436A8 (pt) | composição tópica e veículo para administração de ingredientes farmaceuticamente ou cosmeticamente ativos | |
| AR077549A1 (es) | Una composicion farmaceutica topica para regular el factor de crecimiento endotelial vegf que comprende la (3-trifluoro-metil-fenil)-amida del acido 6-(6-hidroxi-metil-pirimidin-4-iloxi)-naftalen-1-carboxilico. | |
| JP2016538288A5 (enExample) | ||
| MX2014012704A (es) | Composicion farmaceutica topica, proceso de produccion de la composicion farmaceutica topica, uso de la composicion farmaceutica topica y metodo de tratamiento topico de psoriasis, dermatitis atopica o eczemas cronicos. | |
| MX2014014818A (es) | Composicion farmaceutica para el tratamiento de enfermedades inflamatorias de la piel. |